NCT06810635 Polyphenol Metabotypes in People With Diabetes Type 2
| NCT ID | NCT06810635 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Ghent |
| Condition | Type 2 Diabetes Mellitus (T2DM) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-03-04 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-03-04 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).
Eligibility Criteria
Inclusion Criteria: * all participants * between 40-85 years * age-matched individuals without diabetes * BMI between 18.5-30 * no metabolic syndrome * persons with T2DM * at leats 2 years of clinical diagnoses of T2DM * stable medication use for at least 1 month Exclusion Criteria: * pregnancy of breastfeeding * in last month * acute use of anti/pre/probiotics * start of new drug or dietary supplements * major changes in diet * major lifestyle changes * diseases * Gastrointestinal diseases (inflammatory bowel disease) * Bariatric surgery * Other forms of diabetes (cystic fibrosis/MODY/T1DM) * Heart problems (NYHA 3/4) or previous cardiovascular events * Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis * Lung problems (COPD - GOLD 3/4), cystic fibrosis * Uncontrolled thyroid function disruption in the past 6 months * Intake of coumarin derivatives and direct oral anticoagulant medication * Anti-cancer treatment: chemo-/immunotherapy * Immonosuppressants (transplant) * Antiepileptic drugs
Contact & Investigator
Bruno Lapauw, Professor
PRINCIPAL INVESTIGATOR
University Hospital, Ghent
Frequently Asked Questions
Who can join the NCT06810635 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Type 2 Diabetes Mellitus (T2DM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06810635 currently recruiting?
Yes, NCT06810635 is actively recruiting participants. Contact the research team at jan.stautemas@ugent.be for enrollment information.
Where is the NCT06810635 trial being conducted?
This trial is being conducted at Ghent, Belgium, Ghent, Belgium.
Who is sponsoring the NCT06810635 clinical trial?
NCT06810635 is sponsored by University Hospital, Ghent. The principal investigator is Bruno Lapauw, Professor at University Hospital, Ghent. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.